Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARV-027 phase 1 study in healthy male participants and participants with spinal and bulbar muscular atrophy
NL-OMON60356Phase 1Recruiting
- Sponsor
- Arvinas
- Start
- Jan 2026
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of ARV-027 in spinal and bulbar muscular atrophy (SBMA) (2 arms), sponsored by Arvinas. Started Jan 2026; status: recruiting.
02
Drugs
ARV-027
03
Conditions
spinal and bulbar muscular atrophy (SBMA)
Beyond the preview
Go deeper on NL-OMON60356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60356.